NCT00406419 - A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE) | Biotech Hunter

Enrollment

1,015

Participants

Timeline

Start Date

December 27, 2006

Primary Completion Date

October 6, 2009

Study Completion Date

April 22, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Methotrexate

Methotrexate tablet was administered orally at a dose 7.5-25 mg

DRUG

ocrelizumab

Ocrelizumab was administered via IV infusion at a dose specified in arm description

DRUG

Placebo

Matching placebo to ocrelizumab was administered via IV infusion

Trial Locations (1)

Trial Information Support Line, South San Francisco